ImmuPharma PLC
("ImmuPharma" or the "Company")
ANNUAL REPORT AND ACCOUNTS POSTED TO SHAREHOLDERS
NOTICE OF ANNUAL GENERAL MEETING ON 30 JUNE 2017 @ 10.30 AM
INVESTOR PRESENTATION TO FOLLOW AT 11.30 AM
VENUE: SKY LIGHT CITY, 50 BASINGHALL STREET, LONDON, EC2
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that today the Annual Report and Accounts for the year ended 31 December 2016 has today been posted to shareholders.
This report includes the 'Annual Report of the Annual General Meeting' ('AGM') as well as the 'Notice of the 2017 AGM', which will be available later today, in electronic form, for download on the Company's website www.immupharma.org.
ImmuPharma's AGM will be held on Friday 30 June at 10:30am at Sky Light City Tower, 50 Basinghall Street, EC2V 5DE.
Investor Meeting @ 11.30am on 30 June 2017
ImmuPharma has confirmed that it will be hosting an Investor Presentation and luncheon immediately following the Company's Annual General Meeting at 11.30am. Please contact Lisa Baderoon at lisa.baderoon@immupharma.com if you would like to attend this event.
|
-Ends-
|
For further information please contact:
|
ImmuPharma plc (www.immupharma.org)
|
+ 44 (0) 20 7152 4080
|
|
Tim McCarthy, Chairman
|
|
|
Lisa Baderoon, Head of Investor Relations
Twitter: @immupharma
|
+ 44 (0) 7721 413496
|
|
|
|
|
Northland Capital Partners Limited (Joint Broker)
Patrick Claridge, David Hignell, Corporate Finance
Rob Rees, Corporate Broking
|
+44 (0)20 3861 6625
|
|
|
|
|
|
|
|
|
|
|